CN104045547B - A kind of Sodium.alpha.-ketopropionate recrystallization preparation method - Google Patents

A kind of Sodium.alpha.-ketopropionate recrystallization preparation method Download PDF

Info

Publication number
CN104045547B
CN104045547B CN201410315976.8A CN201410315976A CN104045547B CN 104045547 B CN104045547 B CN 104045547B CN 201410315976 A CN201410315976 A CN 201410315976A CN 104045547 B CN104045547 B CN 104045547B
Authority
CN
China
Prior art keywords
sodium
alpha
ketopropionate
aqueous solution
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410315976.8A
Other languages
Chinese (zh)
Other versions
CN104045547A (en
Inventor
蒋志君
陈幸幸
姜幸
黄小棠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JIANGSU CHANGTAI PHARMACEUTICAL CO Ltd
Original Assignee
JIANGSU PHARMAMAX Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JIANGSU PHARMAMAX Co Ltd filed Critical JIANGSU PHARMAMAX Co Ltd
Priority to CN201410315976.8A priority Critical patent/CN104045547B/en
Publication of CN104045547A publication Critical patent/CN104045547A/en
Application granted granted Critical
Publication of CN104045547B publication Critical patent/CN104045547B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/43Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides a kind of Sodium.alpha.-ketopropionate recrystallization preparation method, comprise the following steps: (1) prepares the Sodium.alpha.-ketopropionate aqueous solution: Sodium.alpha.-ketopropionate crude product is dissolved in purified water, cross and filter inorganic impurity; (2) Sodium.alpha.-ketopropionate wet product is prepared: dropped to by the Sodium.alpha.-ketopropionate aqueous solution in ice bath anhydrous alcohol for medical use, Sodium.alpha.-ketopropionate crystallization, filter to obtain wet product; (3) Sodium.alpha.-ketopropionate finished product is prepared: wet product is through drying under reduced pressure, and pulverizing of sieving, inspection and finished product packing, obtain lily Sodium.alpha.-ketopropionate solid.The recyclable recycling of solvent environmental protection of the present invention; Simple process is controlled, and operability is high, and yield is more than 85%, is applicable to suitability for industrialized production; Under D level clean environment, this technique can obtain the highly purified Sodium.alpha.-ketopropionate of high-quality, and microbial limit meets the requirement of respiratory tract administration preparation.

Description

A kind of Sodium.alpha.-ketopropionate recrystallization preparation method
Technical field
The present invention relates to medical art, refer in particular to a kind of Sodium.alpha.-ketopropionate recrystallization preparation method.
Background technology
Sodium.alpha.-ketopropionate, chemical name Acetylformic acid sodium salt, structural formula is such as formula one:
Sodium.alpha.-ketopropionate is the sodium salt of pyruvic acid, and the simplest alpha-ketoacid of pyruvic acid, plays important role in the metabolism of biology, is important metabolic intermediate, has again excellent oxidation-resistance.Sodium.alpha.-ketopropionate is the stable existence form of pyruvic acid, has purposes widely at present in pharmacy and scientific research, simultaneously also as fitness and weight losing dietary supplements, in food, makeup.But Sodium.alpha.-ketopropionate liquid preparation is is still researched and developed in the most promising application of Sodium.alpha.-ketopropionate, for clinical economics aspect.
Current industrial production Sodium.alpha.-ketopropionate mainly first adopts chemical synthesis and fermentation method to obtain high purity pyruvic acid, and the then obtained Pyruvic acid sodium salt with caustic soda or sodium bicarbonate etc., namely a small amount of ethanolic soln drip washing obtain finished product.This type of not purified product, often can not be directly used in pharmacy and scientific research.China does not have bulk drug rank Sodium.alpha.-ketopropionate to sell at present, and the report about Sodium.alpha.-ketopropionate recrystallization method is also few.
Summary of the invention
The invention reside in and prepare Problems existing for current Sodium.alpha.-ketopropionate, and a kind of Sodium.alpha.-ketopropionate recrystallization preparation method that proposition overcomes the above problems.
To achieve these objectives, the present invention adopts following technical scheme:
A kind of Sodium.alpha.-ketopropionate recrystallization preparation method, comprises the following steps:
(1) prepare the Sodium.alpha.-ketopropionate aqueous solution: Sodium.alpha.-ketopropionate crude product is dissolved in purified water, cross and filter inorganic impurity;
(2) Sodium.alpha.-ketopropionate wet product is prepared: dropped to by the Sodium.alpha.-ketopropionate aqueous solution in ice bath anhydrous alcohol for medical use, Sodium.alpha.-ketopropionate crystallization, filter to obtain wet product;
(3) Sodium.alpha.-ketopropionate finished product is prepared: wet product is through drying under reduced pressure, and pulverizing of sieving, inspection and finished product packing, obtain lily Sodium.alpha.-ketopropionate solid.
Wherein,
In described step (1), the weightmeasurement ratio (W/V) of Sodium.alpha.-ketopropionate and water is 1:2.1.
In described step (2), the volume ratio (V/V) of the Sodium.alpha.-ketopropionate aqueous solution and ethanol is 1:(4-12).
In described step (2), the rate of addition of the Sodium.alpha.-ketopropionate aqueous solution controls at 2-5 drop/sec.
In described step (3), drying under reduced pressure temperature is 50 DEG C-80 DEG C.
Sodium.alpha.-ketopropionate recrystallization preparation method of the present invention, tool has the following advantages:
1 the present invention adopts Sodium.alpha.-ketopropionate first to dissolve completely in water, after filtering, filtrate adds to the technique of crystallization in pharmaceutical grade anhydrous ethanol, compared to the mode only adopting the crystallization of washing with alcohol Sodium.alpha.-ketopropionate of traditional technology, can effectively control mechanical impurity and particulate matter;
2 the present invention adopt Sodium.alpha.-ketopropionate first first to dissolve completely in water, after filtration, filtrate is added to the technique of crystallization in pharmaceutical grade anhydrous ethanol, the mode of >=90% washing with alcohol purifying acetone acid sodium is adopted compared to traditional technology, not only effectively can filter out inorganic impurity, yield is also more than 85%;
Separating out Sodium.alpha.-ketopropionate in 3 ethanol is an exothermic process.The present invention adopts ice bath crystallization, and controlling the rate of addition of filtrate is 2-5 drop/sec, effectively temperature of reaction is controlled below 5 DEG C, not only can the solubleness of Sodium.alpha.-ketopropionate in reduction system, improves crystallization yield; Can also avoid, because temperature of reaction height produces other organic impurity, improve the quality of product simultaneously;
4 the present invention are at the sample of D level clean area recrystallization, and its microbial limit meets the requirement of respiratory tract administration preparation;
4 the present invention use the recyclable recycling of solvent environmental protection;
5 present invention process are easy to be controlled, and product is stablized, and are applicable to suitability for industrialized production.
Accompanying drawing explanation
Fig. 1 is production process route block diagram of the present invention;
Fig. 2 is the HPLC collection of illustrative plates that the related substance of Sodium.alpha.-ketopropionate finished product prepared by method of the present invention detects;
Fig. 3 is the IR collection of illustrative plates of Sodium.alpha.-ketopropionate finished product prepared by method of the present invention;
Fig. 4 is the XRD figure spectrum of Sodium.alpha.-ketopropionate finished product prepared by method of the present invention.
Embodiment
The present invention is further illustrated below by embodiment.Method in embodiment in the present invention is only provide for illustration of the present invention, instead of limitation of the present invention.
Embodiment 1
Take 100.01g Sodium.alpha.-ketopropionate in 250ml beaker, add 100ml purified water, stir, ultrasonic dissolution.Increase progressively with 10ml successively and slowly add purified water, dissolve completely, add 210ml altogether to Sodium.alpha.-ketopropionate, recording solution temperature is 30.4 DEG C.With the water system membrane filtration of 0.22 μm, obtain the 264ml Sodium.alpha.-ketopropionate aqueous solution;
Measure the 50ml Sodium.alpha.-ketopropionate aqueous solution, be added in 125ml separating funnel, slowly drop in the 200ml ethanol (ice-water bath) under whipped state, dropwise, stir 30 minutes at 0-5 DEG C, filter immediately, obtain Sodium.alpha.-ketopropionate wet product;
By the vacuum drying oven drying under reduced pressure about 2 hour of above-mentioned wet product at 50 DEG C, weigh, detect related substance.Result is as shown in table 1.
Embodiment 2
The preparation of the Sodium.alpha.-ketopropionate aqueous solution is with embodiment 1;
Measure the 50ml Sodium.alpha.-ketopropionate aqueous solution, be added in 125ml separating funnel, slowly drop in the 400ml ethanol (ice-water bath) under whipped state, dropwise, stir 30 minutes at 0-5 DEG C, filter immediately, obtain Sodium.alpha.-ketopropionate wet product;
By the vacuum drying oven drying under reduced pressure about 2 hour of above-mentioned wet product at 50 DEG C, weigh, detect related substance.Result is as shown in table 1.
Embodiment 3
The preparation of the Sodium.alpha.-ketopropionate aqueous solution is with embodiment 1;
Measure the 50ml Sodium.alpha.-ketopropionate aqueous solution, be added in 125ml separating funnel, slowly drop in the 500ml ethanol (ice-water bath) under whipped state, dropwise, stir 30 minutes at 0-5 DEG C, filter immediately, obtain Sodium.alpha.-ketopropionate wet product;
By the vacuum drying oven drying under reduced pressure about 2 hour of above-mentioned wet product at 50 DEG C, weigh, detect related substance.Result is as shown in table 1.
Embodiment 4
The preparation of the Sodium.alpha.-ketopropionate aqueous solution is with embodiment 1;
Measure the 50ml Sodium.alpha.-ketopropionate aqueous solution, be added in 125ml separating funnel, slowly drop in the 600ml ethanol (ice-water bath) under whipped state, dropwise, stir 30 minutes at 0-5 DEG C, filter immediately, obtain Sodium.alpha.-ketopropionate wet product;
By the vacuum drying oven drying under reduced pressure about 2 hour of above-mentioned wet product at 50 DEG C, weigh, detect related substance.Result is as shown in table 1.
The Sodium.alpha.-ketopropionate that table 1 embodiment 1-4 obtains adopts HPLC to carry out defects inspecting.
Test item Embodiment 1 Embodiment 2 Embodiment 3 Embodiment 4
Single maximum contaminant content 0.06% 0.07% 0.07% 0.06%
Total impurities content 0.17% 0.21% 0.20% 0.19%
Embodiment 5
The preparation of the Sodium.alpha.-ketopropionate aqueous solution is with embodiment 1;
Measure the 50ml Sodium.alpha.-ketopropionate aqueous solution, be added in 125ml separating funnel, slowly drop in the 400ml ethanol (ice-water bath) under whipped state, dropwise, stir 30 minutes at 0-5 DEG C, filter immediately, obtain Sodium.alpha.-ketopropionate wet product;
By the vacuum drying oven drying under reduced pressure about 2 hour of above-mentioned wet product at 80 DEG C, weigh, detect related substance.
The Sodium.alpha.-ketopropionate that table 2 embodiment 2 and 5 obtains adopts HPLC to carry out defects inspecting.
Embodiment 6
Experiment is carried out under D level clean environment.
At ambient temperature, the Sodium.alpha.-ketopropionate (crude product) of 300g is joined in the beaker of the 1000-ml of suitable magnetic stir bar, adds about 600ml purified water, open magnetic stirring apparatus, after dissolving is uniformly dispersed, continues to add 30ml purified water and make it dissolve completely, close magnetic stirring apparatus;
Use the aqueous phase millipore filtration of 0.22 μm to build filtration unit 1 (core filtration), open pump, filtered by the solution in above-mentioned beaker, filtrate is transferred to another 1L graduated cylinder.Filtration terminates rear closedown pump.Liquid in graduated cylinder is the Sodium.alpha.-ketopropionate aqueous solution, stand-by;
Appropriate (be 8:1 with the volume ratio of the Sodium.alpha.-ketopropionate aqueous solution) ethanol is added in 10L beaker, put into suitable agitation, put into suitable ice bath device (liquid level of ethanol is lower than the liquid level of frozen water), be placed on magnetic stirring apparatus, open magnetic stirring apparatus, the temperature of ethanol is made to control at 0 ~ 5 DEG C, stand-by;
Progressively be added in 500-ml pear shape separatory funnel by the Sodium.alpha.-ketopropionate aqueous solution, be fixed on iron stand, what drop to whipped state fills in the 10L beaker of 0 ~ 5 DEG C of dehydrated alcohol, controls rate of addition (2-5 drop/sec), and white solid is separated out.After being added dropwise to complete, continue stirring 10 minutes.Close magnetic stirring apparatus.Guarantee there is ice cube in ice bath device in whole process always;
Use fast qualitative filter paper to build filtration unit 2 (Büchner funnel), open pump, the crystallization solution in 10L beaker in upper step is filtered immediately, obtains Sodium.alpha.-ketopropionate wet product;
Sample is laid on clean pallet and carries out vacuum-drying, control temperature 50 DEG C; Control weight loss on drying≤0.5%, dry 2 hours of rear continuation up to standard, this is Sodium.alpha.-ketopropionate dry product;
Sodium.alpha.-ketopropionate dry product is pulverized grinding by No. 3 sieves; This is Sodium.alpha.-ketopropionate finished product; By Sodium.alpha.-ketopropionate finished product according to carrying out weighing bottling.Finished product sampling detects.This technique repeats 3 batches, and 3 batches of yields are respectively 87%, 87% and 88%, and 3 batch weight crystal product detected results are as shown in table 3:
Table 3 recrystallization finished product detection result
3 batches of finished appearance, white is to off-white color crystalline powder; Weight loss on drying < 0.5%; Vitriol < 100ppm; Muriate < 100ppm; Iron < 10ppm; Arsenic < 1ppm; Heavy metal < 10ppm; Free acid 0.01%, residual solvent (ethanol) does not detect; Content (in dry product) 100%; Related substance, maximum single impurity < 0.1%, total impurities 0.1%, meets ICHQ3A (R2) new raw material medicine impurity research governing principle; The requirement of microbial limit meets " Chinese Pharmacopoeia " version respiratory tract administration preparation in 2010.Fig. 2 is shown in by the HPLC collection of illustrative plates that I1000020 batch of corresponding related substance detects, and IR spectrogram is shown in Fig. 3, and XRD spectra is shown in Fig. 4.

Claims (3)

1. a Sodium.alpha.-ketopropionate recrystallization preparation method, is characterized in that, comprises the following steps:
(1) prepare the Sodium.alpha.-ketopropionate aqueous solution: Sodium.alpha.-ketopropionate crude product is dissolved in purified water, cross and filter inorganic impurity;
(2) Sodium.alpha.-ketopropionate wet product is prepared: dropped to by the Sodium.alpha.-ketopropionate aqueous solution in ice bath anhydrous alcohol for medical use, Sodium.alpha.-ketopropionate crystallization, filter to obtain wet product;
(3) Sodium.alpha.-ketopropionate finished product is prepared: wet product is through drying under reduced pressure, and pulverizing of sieving, checks and finished product packing, obtain lily Sodium.alpha.-ketopropionate solid;
In described step (1), the weightmeasurement ratio (W/V) of Sodium.alpha.-ketopropionate and water is 1:2.1;
In described step (2), the volume ratio (V/V) of the Sodium.alpha.-ketopropionate aqueous solution and ethanol is 1:(4-12);
In described step (2), the rate of addition of the Sodium.alpha.-ketopropionate aqueous solution controls at 2-5 drop/sec.
2. Sodium.alpha.-ketopropionate recrystallization preparation method according to claim 1, is characterized in that, in described step (3), drying under reduced pressure temperature is 50 DEG C-80 DEG C.
3. Sodium.alpha.-ketopropionate recrystallization preparation method according to claim 1, is characterized in that, described preparation process is carried out under D level clean environment.
CN201410315976.8A 2014-07-03 2014-07-03 A kind of Sodium.alpha.-ketopropionate recrystallization preparation method Active CN104045547B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410315976.8A CN104045547B (en) 2014-07-03 2014-07-03 A kind of Sodium.alpha.-ketopropionate recrystallization preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410315976.8A CN104045547B (en) 2014-07-03 2014-07-03 A kind of Sodium.alpha.-ketopropionate recrystallization preparation method

Publications (2)

Publication Number Publication Date
CN104045547A CN104045547A (en) 2014-09-17
CN104045547B true CN104045547B (en) 2016-01-06

Family

ID=51498992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410315976.8A Active CN104045547B (en) 2014-07-03 2014-07-03 A kind of Sodium.alpha.-ketopropionate recrystallization preparation method

Country Status (1)

Country Link
CN (1) CN104045547B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103331C (en) * 2000-01-21 2003-03-19 无锡轻工大学 Process for extracting pyruvic acid from fermented liquid of pyruvic acid and preparing sodium pyrouvate
CN101205181A (en) * 2007-11-12 2008-06-25 南昌大学 Method for extracting and separating sodium ketopropionate from acetonic acid fermentation liquid by double membrane two-step process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103331C (en) * 2000-01-21 2003-03-19 无锡轻工大学 Process for extracting pyruvic acid from fermented liquid of pyruvic acid and preparing sodium pyrouvate
CN101205181A (en) * 2007-11-12 2008-06-25 南昌大学 Method for extracting and separating sodium ketopropionate from acetonic acid fermentation liquid by double membrane two-step process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
发酵法生产丙酮酸钠提取工艺的研究;赵南等;《江西农业学报》;20101231;第22卷(第3期);第161-162页 *

Also Published As

Publication number Publication date
CN104045547A (en) 2014-09-17

Similar Documents

Publication Publication Date Title
CN101723934B (en) Method for refining fasudil hydrochloride
CN104177370B (en) A kind of method preparing high-load sesamin from sesame seed meal
CN102558182B (en) Ertapenem sodium crystal form E and preparation method thereof
CN105273014B (en) A kind of preparation method of high-content cape jasmine glycosidal crystalline
JP6114308B2 (en) Rutin-enriched extract and method for producing the same
CN101143887B (en) Method for separating and preparing corosolicacid in loquat leaf
CN102351929B (en) Preparation method of high-purity breviscapine active pharmaceutical ingredient
CN113264817B (en) Curcumin crystallization method and application thereof
CN104017038A (en) Method for preparing and purifying naringin
CN101891740A (en) Method for extracting laburnine from upper part of thermopsis lanceolate
CN109422642B (en) Refining method of benzoic acid, production method and equipment of pharmaceutical grade sodium benzoate
CN104045547B (en) A kind of Sodium.alpha.-ketopropionate recrystallization preparation method
CN103275049B (en) Method for preparing myricetin by using vine tea and application of pyrosulfite
CN104311616A (en) Method for extracting high-purity esculine and fraxin from Cortex Fraxini
CN102557918A (en) Ibuprofen sodium compound and new preparation method thereof
CN102010439A (en) Production process for extracting yolk lecithin
CN109134331A (en) The synthetic method of azithromycin genotoxicity impurity
CN104961740A (en) Riboflavin-containing solid preparation and preparation method thereof
CN102603819A (en) Preparation method of rosavin
CN103172530A (en) Preparation method of tolfenamic acid
CN104140391A (en) Method for separating and purifying highly pure Euphorbia factor from moleplant seed
CN106279333B (en) A kind of hyodesoxycholic acid crystallization processes method of optimization
CN106187799B (en) A method of preparing DL-lysine hydrochloride
CN102295528B (en) Method for extracting dulcite from xylitol mother liquid
CN103910747B (en) A kind of Olanzapine medicine crystal formation F and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address

Address after: 225300 No.1, South Batang Road, China medicine city, Taizhou City, Jiangsu Province

Patentee after: Jiangsu Changtai Pharmaceutical Co.,Ltd.

Address before: Building G22, Phase III, Tai Road and Yuannan Road, China Pharmaceutical City, Taizhou City, Jiangsu Province, 225300

Patentee before: JIANG SU PHARMAMAXCORP Co.,Ltd.

CP03 Change of name, title or address